Month: September 2020

– Virtual event to take place from 8:00 a.m. to 9:30 a.m. EDT –HAMILTON, Bermuda, Sept. 24, 2020 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways that are implicated across a spectrum of diseases, today announced that the company’s virtual Rilonacept Analyst Day will now take place on Tuesday, September 29th, 2020 from 8:00 a.m. to 9:30 a.m. Eastern Daylight Time.The event will feature presentations from the Kiniksa management team on the market opportunity for rilonacept in recurrent pericarditis as well as the company’s continued commercial preparations and launch strategy. Additionally, guest speaker Paul Cremer, MD, Cardiovascular Medicine, Cleveland Clinic, will review the...

L’ASSOMPTION, Quebec, Sept. 24, 2020 (GLOBE NEWSWIRE) — Corporation Terranueva (CSE : TEQ) ) (the “Corporation” or “Terranueva”), one of the 6 companies in Québec holding a licence from Health Canada to develop cannabis products for medical and recreational purposes, is pleased to announce that Economic Development Canada (“EDC”) has granted a loan of $500,000 to the business to support its day-to-day operations.This assistance from EDC comes from the Regional Relief and Recovery Fund (“RRRFˮ), relating to the measures of Canada’s Economic Response Plan aimed at responding effectively to the COVID-19 pandemic.“The COVID-19 pandemic has placed significant pressure on corporate liquidity. We are therefore very happy to be able to count on this invaluable financial support from EDC via the RRRFˮ, underlines Francisco Perez Junior,...

L’ASSOMPTION, Québec, 24 sept. 2020 (GLOBE NEWSWIRE) — Corporation Terranueva (CSE : TEQ) (la « Société » ou « Terranueva »), une des 6 sociétés québécoises détentrices d’une licence de Santé Canada permettant de développer des produits médicinaux et récréatifs à base de cannabis, est heureuse d’annoncer que Développement Économique Canada (« DEC ») a accordé un prêt de 500 000$ à l’entreprise afin de soutenir ses opérations courantes.Cette aide du DEC provient du Fonds d’aide et de relance régionale (« FARR »), lequel complète les mesures du Plan d’intervention économique du Canada afin de répondre efficacement à la COVID-19.« La pandémie de COVID-19 a entrainé une importante pression sur les liquidités des entreprises. Nous sommes ainsi très heureux de pouvoir compter sur ce précieux soutien financier de DEC via le FARR...

First quarter sales of $401 million, down 26% from the prior year reflecting the impact of COVID-19First quarter GAAP diluted loss per share from continuing operations of $(0.40)Adjusted diluted earnings per share from continuing operations of $0.17, which exclude the impact of the Composites sale and other itemsWOOD DALE, Ill., Sept. 24, 2020 (GLOBE NEWSWIRE) — AAR CORP. (NYSE: AIR) today reported first quarter Fiscal Year 2021 consolidated sales of $400.8 million and loss from continuing operations of $13.9 million, or $0.40 per diluted share. For the first quarter of the prior year, the Company reported sales of $541.5 million and income from continuing operations of $17.1 million, or $0.49 per diluted share. Our adjusted diluted earnings per share from continuing operations in the first quarter of Fiscal Year 2021 were $0.17...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual presentations at the Ophthalmology Futures Retina Forum, European Society of Retina Specialists (Euretina) congress and the Annual Meeting of the American Academy of Optometry (AAOpt).ProQR’s presentation at Ophthalmology Futures Retina ForumPresentation title: Advancements in Inherited Retinal Diseases ManagementPresenter: Aniz Girach, MD, Chief Medical Officer of ProQRDate: September 30, 2020ProQR’s presentations at EuretinaPresentation title: Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10)Presenter: Stephen...

Lille, France; Cambridge, M.A.; September 24, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the first patient first visit for ELATIVE, the global, pivotal, Phase 3 study evaluating elafibranor in Primary Biliary Cholangitis (PBC).ELATIVE is a randomized, double blind, placebo-controlled, global multicenter Phase 3 study evaluating the efficacy and safety of elafibranor, a dual PPAR alpha and delta agonist, in PBC. The primary endpoint will evaluate the response to treatment defined by alkaline phosphatase (ALP) < 1.67 x upper limit of normal (ULN), total bilirubin (TB) ≤ ULN and ALP decrease ≥ 15%. Key secondary endpoints will include the effect of elafibranor on normalization of ALP and change in pruritus...

TORONTO, Sept. 24, 2020 (GLOBE NEWSWIRE) — SmartCentres Real Estate Investment Trust (“SmartCentres”) (TSX:SRU.UN) announced today that the trustees of SmartCentres have declared a distribution for the month of September 2020 of CDN $0.15417 per trust unit, representing CDN $1.85 per unit on an annualized basis. Payment will be made on October 15, 2020 to unitholders of record on September 30, 2020.About SmartCentresSmartCentres Real Estate Investment Trust is one of Canada’s largest fully integrated REITs, with a best-in-class portfolio featuring 166 strategically located properties in communities across the country. SmartCentres has $10.4 billion in assets and owns over 34.2 million square feet of income producing value-oriented retail space with 97.8% occupancy, on 3,500 acres of owned land across Canada.SmartCentres continues...

VANCOUVER, British Columbia and MOUNTAIN VIEW, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) — AbCellera and IGM Biosciences, Inc. (Nasdaq: IGMS), announced today that they have entered into a multi-year, multi-target strategic research collaboration and license agreement to facilitate the discovery and development of novel IgM antibodies. AbCellera will generate panels of antibodies for multiple therapeutic targets identified by IGM using       its full-stack, AI-powered antibody discovery technology, and IGM will have the rights to develop and commercialize the novel antibodies resulting from this collaboration. Financial terms of the collaboration were not disclosed.“We believe that AbCellera’s technology will assist us in rapidly identifying the best antibodies against a large number of agonist targets, as well as other historically...

Faits saillantsUn plan quinquennal de dépenses en immobilisations de 19,6 milliards de dollars, soit une augmentation de 800 millions par rapport au plan de l’année précédenteUn dividende de 0,505 $ sur les actions ordinaires pour le quatrième trimestre de 2020, ce qui correspond à une hausse de 5,8 %Une prolongation jusqu’en 2025 de l’objectif de croissance annuelle moyenne de 6 % du dividendeUne nouvelle cible de réduction des émissions de carbone de 75 % d’ici 2035, par rapport à 2019ST. JOHN’S, Terre-Neuve-et-Labrador, 24 sept. 2020 (GLOBE NEWSWIRE) — Fortis Inc. (« Fortis » ou la « Société ») (TSX/NYSE:FTS) a dévoilé aujourd’hui son plan quinquennal de dépenses en immobilisations de 19,6 milliards de dollars pour la période 2021-2025, représentant une augmentation de 800 millions par rapport au plan de l’année précédente. La...

SASKATOON, Saskatchewan, Sept. 24, 2020 (GLOBE NEWSWIRE) — Cameco (TSX: CCO; NYSE: CCJ) will issue its third quarter results before markets open on Wednesday, November 4, 2020.Cameco invites investors and the media to join its third quarter conference call with the company’s senior executives on Wednesday, November 4, 2020 at 8:00 a.m. Eastern.Cameco will discuss trends in the market and the execution of its strategy before opening the call to questions from investors and the media.To join the call, please dial 800-319-4610 (Canada and US toll-free) or 604-638-5340. An operator will put your call through. A live webcast of the conference call will be available from a link at cameco.com. A recorded version of the proceedings will be available on our website shortly after the call, and on post view until midnight, Eastern, December...